Cargando…

Conditional assurance: the answer to the questions that should be asked within drug development

In this paper, we extend the use of assurance for a single study to explore how meeting a study's pre‐defined success criteria could update our beliefs about the true treatment effect and impact the assurance of subsequent studies. This concept of conditional assurance, the assurance of a subse...

Descripción completa

Detalles Bibliográficos
Autores principales: Temple, Jane R., Robertson, Jon R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291040/
https://www.ncbi.nlm.nih.gov/pubmed/33960600
http://dx.doi.org/10.1002/pst.2128
_version_ 1784749050285785088
author Temple, Jane R.
Robertson, Jon R.
author_facet Temple, Jane R.
Robertson, Jon R.
author_sort Temple, Jane R.
collection PubMed
description In this paper, we extend the use of assurance for a single study to explore how meeting a study's pre‐defined success criteria could update our beliefs about the true treatment effect and impact the assurance of subsequent studies. This concept of conditional assurance, the assurance of a subsequent study conditional on success in an initial study, can be used assess the de‐risking potential of the study requiring immediate investment, to ensure it provides value within the overall development plan. If the planned study does not discharge sufficient later phase risk, alternative designs and/or success criteria should be explored. By transparently laying out the different design options and the risks associated, this allows for decision makers to make quantitative investment choices based on their risk tolerance levels and potential return on investment. This paper lays out the derivation of conditional assurance, discusses how changing the design of a planned study will impact the conditional assurance of a future study, as well as presenting a simple illustrative example of how this methodology could be used to transparently compare development plans to aid decision making within an organisation.
format Online
Article
Text
id pubmed-9291040
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-92910402022-07-20 Conditional assurance: the answer to the questions that should be asked within drug development Temple, Jane R. Robertson, Jon R. Pharm Stat Main Papers In this paper, we extend the use of assurance for a single study to explore how meeting a study's pre‐defined success criteria could update our beliefs about the true treatment effect and impact the assurance of subsequent studies. This concept of conditional assurance, the assurance of a subsequent study conditional on success in an initial study, can be used assess the de‐risking potential of the study requiring immediate investment, to ensure it provides value within the overall development plan. If the planned study does not discharge sufficient later phase risk, alternative designs and/or success criteria should be explored. By transparently laying out the different design options and the risks associated, this allows for decision makers to make quantitative investment choices based on their risk tolerance levels and potential return on investment. This paper lays out the derivation of conditional assurance, discusses how changing the design of a planned study will impact the conditional assurance of a future study, as well as presenting a simple illustrative example of how this methodology could be used to transparently compare development plans to aid decision making within an organisation. John Wiley & Sons, Inc. 2021-05-07 2021 /pmc/articles/PMC9291040/ /pubmed/33960600 http://dx.doi.org/10.1002/pst.2128 Text en © 2021 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Main Papers
Temple, Jane R.
Robertson, Jon R.
Conditional assurance: the answer to the questions that should be asked within drug development
title Conditional assurance: the answer to the questions that should be asked within drug development
title_full Conditional assurance: the answer to the questions that should be asked within drug development
title_fullStr Conditional assurance: the answer to the questions that should be asked within drug development
title_full_unstemmed Conditional assurance: the answer to the questions that should be asked within drug development
title_short Conditional assurance: the answer to the questions that should be asked within drug development
title_sort conditional assurance: the answer to the questions that should be asked within drug development
topic Main Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291040/
https://www.ncbi.nlm.nih.gov/pubmed/33960600
http://dx.doi.org/10.1002/pst.2128
work_keys_str_mv AT templejaner conditionalassurancetheanswertothequestionsthatshouldbeaskedwithindrugdevelopment
AT robertsonjonr conditionalassurancetheanswertothequestionsthatshouldbeaskedwithindrugdevelopment